Prospective study on metabolic factors and risk of prostate cancer

Cancer

Volumn 118, Issue 24, 2012, Pages 6199-6206

  Häggström, Christel ^a   Stocks, Tanja ^a,b   Ulmert, David ^c,d   Bjørge, Tone ^e,f   Ulmer, Hanno ^g   Hallmans, Göran ^h   Manjer, Jonas ^c   Engeland, Anders ^e,f   Nagel, Gabriele ^i,j   Almqvist, Martin ^c   Selmer, Randi ^f   Concin, Hans ^j   Tretli, Steinar ^k   Jonsson, Håkan ^h   Stattin, Pär ^a,d  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b Centre for Health and Society   (Denmark)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY OF BERGEN   (Norway)

^f NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^g INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^h UMEÅ UNIVERSITY   (Sweden)

ⁱ UNIVERSITY OF ULM   (Germany)

^j AGENCY FOR PREVENTIVE AND SOCIAL MEDICINE   (Austria)

^k CANCER REGISTRY OF NORWAY   (Norway)

more..

Author keywords

blood pressure; body mass index; cohort study; epidemiology; metabolic factors; metabolic syndrome; prostate cancer

Indexed keywords

CHOLESTEROL; GLUCOSE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CANCER MORTALITY; CANCER RISK; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLISM; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL; FOLLOW-UP STUDIES; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL RATE; TRIGLYCERIDES;

EID: 84870716925     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27677     Document Type: Article

References (51)

1. Hsing AW, Chokkalingam AP,. Prostate cancer epidemiology. Front Biosci. 2006; 11: 1388-1413.
2. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108.
3. Barnard RJ, Aronson WJ, Tymchuk CN, Ngo TH,. Prostate cancer: another aspect of the insulin-resistance syndrome? Obes Rev. 2002; 3: 303-308.
4. Freedland SJ, Aronson WJ,. Examining the relationship between obesity and prostate cancer. Rev Urol. 2004; 6: 73-81.
5. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002; 288: 2709-2716.
6. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS,. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation. 2004; 109: 42-46.
7. MacInnis RJ, English DR,. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control. 2006; 17: 989-1003.
8. Engeland A, Tretli S, Bjorge T,. Height, body mass index, and prostate cancer: a follow-up of 950000 Norwegian men. Br J Cancer. 2003; 89: 1237-1242.
9. Stocks T, Hergens MP, Englund A, Ye W, Stattin P,. Blood pressure, body size and prostate cancer risk in the Swedish Construction Workers cohort. Int J Cancer. 2010; 127: 1660-1668.
10. Cao Y, Ma J,. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2011; 4: 486-501.
11. Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ,. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev. 2001; 10: 345-353.
12. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ,. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348: 1625-1638.
13. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM,. Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005; 293: 194-202.
14. Stocks T, Rapp K, Bjorge T, et al. Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med. 2009; 6: e1000201.
15. Hsing AW, Sakoda LC, Chua S Jr,. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr. 2007; 86: s843-s857.
16. Grundmark B, Garmo H, Loda M, Busch C, Holmberg L, Zethelius B,. The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes. Cancer Epidemiol Biomarkers Prev. 2010; 19: 2088-2096.
17. Martin RM, Vatten L, Gunnell D, Romundstad P, Nilsen TI,. Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes Control. 2009; 20: 1181-1192.
18. Van Hemelrijck M, Garmo H, Holmberg L, et al. Prostate cancer risk in the Swedish AMORIS study: the interplay among triglycerides, total cholesterol, and glucose. Cancer. 2011; 117: 2086-2095.
19. Tande AJ, Platz EA, Folsom AR,. The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol. 2006; 164: 1094-1102.
20. Wallner LP, Morgenstern H, McGree ME, et al. The effects of metabolic conditions on prostate cancer incidence over 15 years of follow-up: results from the Olmsted County Study. BJU Int. 2011; 107: 929-935.
21. Clarke R, Shipley M, Lewington S, et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol. 1999; 150: 341-353.
22. Whitlock G, Clark T, Vander Hoorn S, et al. Random errors in the measurement of 10 cardiovascular risk factors. Eur J Epidemiol. 2001; 17: 907-909.
23. Stocks T, Borena W, Strohmaier S, et al. Cohort Profile: The Metabolic syndrome and Cancer project (Me-Can). Int J Epidemiol. 2010; 39: 660-667.
24. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R,; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360: 1903-1913.
25. Jonsson H, Holmstrom B, Duffy SW, Stattin P,. Uptake of prostate-specific antigen testing for early prostate cancer detection in Sweden [published online ahead of print December 10, 2010]. Int J Cancer.
26. Bratt O, Berglund A, Adolfsson J, Johansson JE, Tornblom M, Stattin P,; Steering Committee of the Swedish National Prostate Cancer Register. Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: a population-based study from the National Prostate Cancer Register of Sweden. Scand J Urol Nephrol. 2010; 44: 384-390.
27. Kvale R, Auvinen A, Adami HO, et al. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst. 2007; 99: 1881-1887.
28. Vutuc C, Schernhammer ES, Haidinger G, Waldhor T,. Prostate cancer and prostate-specific antigen (PSA) screening in Austria. Wien Klin Wochenschr. 2005; 117: 457-461.
29. Bland JM, Altman DG,. Multiple significance tests: the Bonferroni method. BMJ. 1995; 310: 170.
30. Fibrinogen Studies Collaboration, Wood AM, White I, Thompson SG, Lewington S, Danesh J,. Regression dilution methods for meta-analysis: assessing long-term variability in plasma fibrinogen among 27,247 adults in 15 prospective studies. Int J Epidemiol. 2006; 35: 1570-1578.
31. Emberson JR, Whincup PH, Morris RW, Walker M, Lowe GD, Rumley A,. Extent of regression dilution for established and novel coronary risk factors: results from the British Regional Heart Study. Eur J Cardiovasc Prev Rehabil. 2004; 11: 125-134.
32. Sandblom G, Dufmats M, Olsson M, Varenhorst E,. Validity of a population-based cancer register in Sweden-an assessment of data reproducibility in the South-East region Prostate Cancer Register. Scand J Urol Nephrol. 2003; 37: 112-119.
33. Larsen IK, Smastuen M, Johannesen TB, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009; 45: 1218-1231.
34. Rapp K, Schroeder J, Klenk J, et al. Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia. 2006; 49: 945-952.
35. Rodriguez C, Freedland SJ, Deka A, et al. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2007; 16: 63-69.
36. Giovannucci E, Rimm EB, Liu Y, et al. Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst. 2003; 95: 1240-1244.
37. Pischon T, Boeing H, Weikert S, et al. Body size and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev. 2008; 17: 3252-3261.
38. Kasper JS, Giovannucci E,. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006; 15: 2056-2062.
39. Bonovas S, Filioussi K, Tsantes A,. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia. 2004; 47: 1071-1078.
40. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE,. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol. 2005; 161: 147-152.
41. Leitzmann MF, Ahn J, Albanes D, et al. Prostate, Lung, Colorectal, and Ovarian Trial Project Team. Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control. 2008; 19: 1267-1276.
42. Stocks T, Lukanova A, Rinaldi S, et al. Insulin resistance is inversely related to prostate cancer: a prospective study in Northern Sweden. Int J Cancer. 2007; 120: 2678-2686.
43. Discacciati A, Orsini N, Andersson SO, Andren O, Johansson JE, Wolk A,. Body mass index in early and middle-late adulthood and risk of localised, advanced and fatal prostate cancer: a population-based prospective study. Br J Cancer. 2011; 105: 1061-1068.
44. Buschemeyer WC 3rd, Freedland SJ,. Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol. 2007; 52: 331-343.
45. Giovannucci E, Michaud D,. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology. 2007; 132: 2208-2225.
46. Batty GD, Kivimaki M, Clarke R, Davey Smith G, Shipley MJ,. Modifiable risk factors for prostate cancer mortality in London: forty years of follow-up in the Whitehall study. Cancer Causes Control. 2011; 22: 311-318.
47. Batty GD, Shipley MJ, Marmot MG, Davey Smith G,; Whitehall Study. Blood pressure and site-specific cancer mortality: evidence from the original Whitehall study. Br J Cancer. 2003; 89: 1243-1247.
48. Huxley R,; Asia Pacific Cohort Studies Collaboration. The impact of modifiable risk factors on mortality from prostate cancer in populations of the Asia-Pacific region. Asian Pac J Cancer Prev. 2007; 8: 199-205.
49. Jaggers JR, Sui X, Hooker SP, et al. Metabolic syndrome and risk of cancer mortality in men. Eur J Cancer. 2009; 45: 1831-1838.
50. Lund Haheim L, Wisloff TF, Holme I, Nafstad P,. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol. 2006; 164: 769-774.
51. Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT,. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev. 2004; 13: 1646-1650.